B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma
B7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints. Besides neuroblastoma, B7-H3 is expresse...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/13/3279 |
| _version_ | 1797592065311244288 |
|---|---|
| author | Cristina Bottino Chiara Vitale Alessandra Dondero Roberta Castriconi |
| author_facet | Cristina Bottino Chiara Vitale Alessandra Dondero Roberta Castriconi |
| author_sort | Cristina Bottino |
| collection | DOAJ |
| description | B7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints. Besides neuroblastoma, B7-H3 is expressed by many pediatric cancers including tumors of the central nervous system, sarcomas, and acute myeloid leukemia. In children, particularly those affected by solid tumors, the therapeutic protocols are aggressive and cause important life-threatening side effects. Moreover, despite the improved survival observed in the last decade, a relevant number of patients show therapy resistance and fatal relapses. Immunotherapy represents a new frontier in the cure of cancer patients and the targeting of tumor antigens or immune checkpoints blockade showed exciting results in adults. In this encouraging scenario, researchers and clinicians are exploring the possibility to use immunotherapeutics targeting B7-H3; these include mAbs and chimeric antigen receptor T-cells (CAR-T). These tools are rapidly evolving to improve the efficacy and decrease the unwanted side effects; drug-conjugated mAbs, bi–tri-specific mAbs or CAR-T, and, very recently, NK cell engagers (NKCE), tetra-specific molecules engaging a tumor-associated antigen and NK cells, have been generated. Preclinical data are promising, and clinical trials are ongoing. Hopefully, the B7-H3 targeting will provide important benefits to cancer patients. |
| first_indexed | 2024-03-11T01:46:08Z |
| format | Article |
| id | doaj.art-69813c3064d14c93bc0c510acdb586e9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T01:46:08Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-69813c3064d14c93bc0c510acdb586e92023-11-18T16:14:39ZengMDPI AGCancers2072-66942023-06-011513327910.3390/cancers15133279B7-H3 in Pediatric Tumors: Far beyond NeuroblastomaCristina Bottino0Chiara Vitale1Alessandra Dondero2Roberta Castriconi3Department of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, ItalyDepartment of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, ItalyDepartment of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, ItalyDepartment of Experimental Medicine (DIMES), University of Genoa, 16132 Genoa, ItalyB7-H3 is a 4Ig transmembrane protein that emerged as a tumor-associated antigen in neuroblastoma. It belongs to the B7 family, shows an immunoregulatory role toward NK and T cells, and, therefore, has been included in the growing family of immune checkpoints. Besides neuroblastoma, B7-H3 is expressed by many pediatric cancers including tumors of the central nervous system, sarcomas, and acute myeloid leukemia. In children, particularly those affected by solid tumors, the therapeutic protocols are aggressive and cause important life-threatening side effects. Moreover, despite the improved survival observed in the last decade, a relevant number of patients show therapy resistance and fatal relapses. Immunotherapy represents a new frontier in the cure of cancer patients and the targeting of tumor antigens or immune checkpoints blockade showed exciting results in adults. In this encouraging scenario, researchers and clinicians are exploring the possibility to use immunotherapeutics targeting B7-H3; these include mAbs and chimeric antigen receptor T-cells (CAR-T). These tools are rapidly evolving to improve the efficacy and decrease the unwanted side effects; drug-conjugated mAbs, bi–tri-specific mAbs or CAR-T, and, very recently, NK cell engagers (NKCE), tetra-specific molecules engaging a tumor-associated antigen and NK cells, have been generated. Preclinical data are promising, and clinical trials are ongoing. Hopefully, the B7-H3 targeting will provide important benefits to cancer patients.https://www.mdpi.com/2072-6694/15/13/3279pediatric tumorsB7-H3immunotherapyclinical trials |
| spellingShingle | Cristina Bottino Chiara Vitale Alessandra Dondero Roberta Castriconi B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma Cancers pediatric tumors B7-H3 immunotherapy clinical trials |
| title | B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma |
| title_full | B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma |
| title_fullStr | B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma |
| title_full_unstemmed | B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma |
| title_short | B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma |
| title_sort | b7 h3 in pediatric tumors far beyond neuroblastoma |
| topic | pediatric tumors B7-H3 immunotherapy clinical trials |
| url | https://www.mdpi.com/2072-6694/15/13/3279 |
| work_keys_str_mv | AT cristinabottino b7h3inpediatrictumorsfarbeyondneuroblastoma AT chiaravitale b7h3inpediatrictumorsfarbeyondneuroblastoma AT alessandradondero b7h3inpediatrictumorsfarbeyondneuroblastoma AT robertacastriconi b7h3inpediatrictumorsfarbeyondneuroblastoma |